# Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

> **NCT01933672** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 33 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** PF-04937319 once-daily
- **DRUG:** PF-04937319 split-dose
- **DRUG:** Sitagliptin once-daily

## Key facts

- **NCT ID:** NCT01933672
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2016-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01933672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01933672, "Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01933672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*